Cardioprotection and m6A RNA, with AML a lower risk, but lower value, opportunity. This focus has been outlined in all the strategic updates released since late 2021, including the last update in August.
On this focus everyone agrees, the only discussion has been over how to achieve the best outcome for shareholders. This is not a simple problem as there are many factors to consider and balance, not least the state of the capital markets.
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-138
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
